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The Saccharomyces cerevisiae prp mutants (prp2 through prpll) are known to be defective in pre-mRNA
splicing at nonpermissive temperatures. We have sequenced the PRP4 gene and shown that it encodes a
52-kilodalton protein. We obtained PRP4 protein-specific antibodies and found that they inhibited in vitro
pre-mRNA splicing, which confirms the essential role of PRP4 in splicing. Moreover, we found that PRP4 is
required early in the spliceosome assembly pathway. Immunoprecipitation experiments with anti-PRP4
antibodies were used to demonstrate that PRP4 is a protein of the U4/U6 small nuclear ribonucleoprotein
particle (snRNP). Furthermore, the U5 snRNP could be immunoprecipitated through snRNP-snRNP interac-
tions in the large U4/U5/U6 complex.
In eucaryotes, nuclear pre-mRNA splicing requires a
number of factors, including small nuclear RNA molecules
(snRNAs) associated in protein complexes known as small
nuclear ribonucleoprotein particles (snRNPs) (reviewed in
32 and 41). The snRNPs assemble onto the pre-mRNA
substrate to form a large splicing complex known as spliceo-
some (6, 16, 17). Five major snRNAs have been found to be
essential for mRNA splicing (reviewed in reference 17a).
The snRNPs containing Ul, U2, and U5 snRNAs consist of
the single snRNA complexed with several specific proteins
(reviewed in reference 30). In contrast, the U4 and U6
snRNAs are found base paired together in the same snRNP
(4, 20). With the exception of U6, the snRNAs possess a
trimethylguanosine (m3G)-modified nucleotide cap at the 5'
end (5). Some of the snRNPs interact directly with the
precursor (9, 45). The Ul snRNP binds to the 5' splice site,
the U2 snRNP binds to the branchpoint, and the U5 snRNP
possibly recognizes the 3' splice site. Binding of Ul and U2
snRNPs to the pre-mRNA is required in early steps of
spliceosome formation. In a later step, the U4/U6 snRNP is
required for splicing; however, no association with the
pre-mRNA at a specific site has been identified, and the role
of the U4/U6 complex is still unknown.
Most aspects of mRNA splicing are conserved between
yeast and mammalian systems. Spliceosome assembly oc-
curs by the same general pathway, which involves splicing-
dependent complexes in both systems (11, 21, 38). The
snRNAs in yeast cells are larger than their mammalian
counterparts, but they contain similar functional domains. In
mammals, the protein components of the spliceosome in-
clude heterogeneous nuclear RNPs (12) and several snRNPs:
seven core proteins common to all snRNPs and some unique
proteins specific to each snRNP (reviewed in reference 30).
However, specific functions have not been determined for
any of them, nor have all of the proteins involved in splicing
been identified. In yeast cells, pre-mRNA splicing also
requires multiple protein factors, but less is known about
these factors. Identification of several proteins required in
yeast pre-mRNA splicing has been possible through the
study of the yeast rna mutants (rna2 to rnall), which were
first identified by Hartwell and are known to be defective in
mRNA splicing at nonpermissive temperatures (19). These
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mutants are now called pre-mRNA-processing (prp) mutants
by researchers in the field. The protein products of several
of the PRP genes have been shown to be directly involved in
the yeast mRNA-splicing process: antibodies directed
against PRP8 immunoprecipitate specific snRNAs (29),
PRP11 is found to be associated with the spliceosome (10),
and PRP2 appears to be an extrinsic spliceosome factor
required at a late stage of spliceosome formation (27). As
yet, however, no specific function has been described for
any protein involved in splicing. We have examined the role
of one of the PRP gene products, the PRP4 protein, in
mRNA splicing and its relationship with the other compo-
nents of the spliceosome. The PRP4 gene has been previ-
ously cloned by genetic complementation, and a 1.6-kilobase
transcript of low abundance has been identified (44). In this
paper, we demonstrate that the PRP4 gene encodes a
52-kilodalton (kDa) protein that is essential for in vitro
mRNA splicing and is required early in the spliceosome
pathway. By using anti-PRP4 antibodies, we show that the
large U4/US/U6 snRNP complex can be immunoprecipi-
tated. We provide evidence that PRP4 is strongly associated
with the U4/U6 snRNP.
MATERIALS AND METHODS
Strains. Escherichia coli JM101 [A(lac-pro) thi supE (F'
traD36 proA+B+, lacP lacZ.AM15)] was used for cloning and
amplification of plasmid DNAs, and strain AR58 (34) was
used for expression of PRP4. The Saccharomyces cerevisiae
strains DBY689 (a leu2.3,2-112 ura3-50 canl-101) and B364B
(ot adel ade2 lys2 tyri his7 ural gall) were used for
preparation of splicing extracts.
mRNA-splicing assay. mRNA-splicing extracts were pre-
pared as described by Lustig et al. (31). Actin precursor was
synthesized in vitro by using SP6 polymerase as described
by Lin et al. (28). Splicing reactions were carried out in a
buffer containing 60 mM KPO4 (pH 7), 3 mM MgCl2, 1 mM
spermidine, 2 mM ATP, 3% polyethylene glycol (PEG), 0.4
nM transcript, and 40% splicing extract, as previously de-
scribed by Newman et al. (35).
Sequencing and sequence analysis. The sequence of PRP4
was determined by subcloning HindIII-BglII, Ball-HindIll,
BglII-PstI, and BglII-BglII fragments into M13mpl8 or
M13mpl9 and sequencing both strands by the dideoxynucle-
otide method (40). Sequences overlapping the restriction
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sites and sequences far from the universal primer were
determined by using synthetic oligonucleotides as primers.
Sequence data were assembled, translated, and analyzed
with the GENED, SEQ, and PEP programs of the BIONET
National Computer Resource for Molecular Biology. All
protein sequences used in homology searches were obtained
with the Intelligenetics QUEST, IFIND, and XFASTP pro-
grams of the National Institutes of Health sequence and
National Biomedical Research Foundation protein data
bases in BIONET.
Plasmid construction. Plasmid pJDB207/PRP4, containing
the wild-type PRP4 gene, was constructed from a 5.6-
kilobase BamHI fragment cloned into pJDB207. This plas-
mid was kindly provided by J. Woolford, Carnegie-Mellon
University, Pittsburgh, Pa. Plasmid M13mpl8/PRP4 was
constructed by subcloning a 2.1-kilobase HindIII-BalI frag-
ment, capable of complementing the prp4 mutation in trans
(44), into the HindlIl and HindII sites of M13mpl8. Two
oligonucleotides with the following sequences were synthe-
sized and used to introduce an NcoI site precisely at the 5'
and 3' ends of the PRP4 gene: 5'-ATATTTACCCATGGTC
CGTTC-3' (21-mer used to introduce Ncol upstream) and
5'-TACTAAATCCATGGCTTTACAC-3' (22-mer used to
introduce NcoI downstream). One of the base changes
modifies the second codon (AGT, serine to GGT, glycine).
The NcoI fragment was inserted in the NcoI cloning site of
the PAR3039/1 vector, a derivative of PAR3039 (49) in which
the unique NdeI site was destroyed by Klenow filling and a
unique NcoI cloning site was created by insertion of Ncol
linkers (5'-CAGCCATGGCTG-3').
Expression of the PRP4 gene in E. coli. The expression
system used consisted of the two compatible plasmids
PAR3039/1 and pGPl-2. Plasmid pGP1-2 carries the T7 RNA
polymerase gene under the control of the PL promoter of
bacteriophage X and the X c1857 gene under the control of
plac promoter. Plasmid pGP1-2 allows expression of the T7
polymerase after heat induction. The expression experi-
ments were done essentially as described by Zerbib et al.
(49). A 5-ml culture was grown at 23°C in L-broth medium in
the presence of isopropyl-,-D-thiogalactopyranoside (IPTG;
4 ,ug/ml), ampicillin (300 ,ug/ml), and kanamycin (60 ,ug/ml).
When the culture reached an A6. of 0.5, the cells were
harvested, suspended in medium without IPTG, and shifted
to 42°C for 30 min to inactivate the heat-sensitive X repres-
sor, followed by growth at 23°C for 16 h. To monitor the
production of PRP4, aliquots of the culture were centrifuged
and suspended in Tris-sucrose buffer (10 mM Tris [pH 7.4],
10% sucrose); typically 80 ,u1 of buffer was added per ml of
culture for every unit of optical density at 600 nm. Loading
buffer was added to the cells, the samples were boiled for 3
min, and 20-,u samples were loaded on a sodium dodecyl
sulfate (SDS)-10% polyacrylamide gel. Proteins were
stained with Coomassie blue.
Production of PRP4 antibody and immunoblot analysis.
Four liters of culture of the overproduced E. coli strain was
grown in the conditions described above. The cells were
collected by centrifugation, washed, and suspended in buffer
(3 ml of buffer per g of cells) containing 50mM Tris (pH 8.0),
5 mM EDTA, 1 mM ,-mercaptoethanol, 4% glycerol, and 1
mM phenylmethylsulfonyl fluoride. The cells were treated
with lysozyme for 1 h at 4°C and then were broken by
freeze-thawing and sonication. The lysate was centrifuged,
the supernatant was discarded, and the pellet was suspended
in Tris-sucrose buffer (1 ml of buffer per g of cells) containing
50 mM Tris (pH 8.0), 5 mM EDTA, 1 mM ,B-mercaptoeth-
anol, 4% glycerol, and 0.5% SDS. After centrifugation at
17,000 rpm in a Sorvall SS34 rotor for 30 min, 100 ,ul of the
supernatant was loaded on an SDS-10% polyacrylamide gel
(25 by 12 by 0.15 cm). Electrophoresis was carried out at 100
V for 20 h. Proteins were stained with Coomassie blue and
destained briefly; the band corresponding to PRP4 was cut
from the gel, crushed, and treated as described by Phizicky
et al. (37). Protein (100 p.g) was injected subcutaneously into
a young New Zealand White rabbit. Boosts of the same
amount of material were injected after 1 month and every 2
weeks for an additional month. The antibodies obtained
were used in immunoblot analysis to detect PRP4 in yeast
extract or in crude lysate prepared from the PRP4-overpro-
ducing E. coli strain. The procedure of electroblotting pro-
teins onto nitrocellulose filters and visualizing with rabbit
antibody and goat anti-rabbit antibody coupled to horserad-
ish peroxidase has been described previously (14, 48).
Antibody inhibition of mRNA splicing in vitro. Antibody
inhibition of mRNA splicing in vitro was done as described
by Chang et al. (10). Yeast extract (4 p.l) was mixed with 3 p.1
of protein A-purified antibodies (0.2 to 20 p.g) and incubated
at 4°C for 30 min. A solution containing 32P-labeled pre-
mRNA and all of the other splicing components was then
added to make a final volume of 10 p.l. The splicing reactions
were carried out as previously described for 20 min at 23°C,
and the RNAs were separated on an 8% polyacrylamide-7 M
urea gel, which was then subjected to autoradiography.
Analysis of splicing complexes. Splicing complexes were
analyzed by nondenaturing polyacrylamide gel electropho-
resis as described by Cheng and Abelson (11). Wild-type
extract (2 p.l) was preincubated for 30 min at 4°C with either
preimmune immunoglobulin G (IgG) or anti-PRP4 IgG puri-
fied by affinity chromatography on protein-A Sepharose, and
standard splicing reactions were carried out. Just before
electrophoresis, a solution containing 60 mM potassium
phosphate (pH 7.0), 3 mM MgCl2, 3% PEG 8000, 8%
glycerol, and heparin (2 p.g/p.l of extract) was added to the
samples. The samples were analyzed by gel electrophoresis
through a 4% polyacrylamide gel (acrylamide/bisacrylamide
ratio of 80: 1) at 300 V for 30 min and then at 230 V for 4 h at
4°C in a buffer containing 20 mM Tris hydrochloride (pH 8.0)
and 1 mM EDTA, as previously described (11).
Immunoprecipitation. Anti-m3G antibody was a generous
gift from R. Luhrmann (Max-Planck Institut, Berlin, Federal
Republic of Germany). RNAs were immunoprecipitated as
described by Cheng and Abelson (11) and Lossky et al. (29).
Antiserum or preimmune serum was coupled to protein
A-Sepharose by incubating 3 p.l of serum with 2.5 mg of
protein A-Sepharose (Pharmacia, Inc.) at 4°C for 1 h in 0.5
ml of NET-2 buffer (50 mM Tris hydrochloride [pH 7.4],
0.05% Nonidet P-40, 150 mM NaCI). The resin was then
washed three times with 1 ml of the same buffer or with NET
buffers of different salt molarities (between 0 and 750 mM
NaCI). Before immunoprecipitation, yeast extract (4 p.l) was
preincubated without substrate under splicing conditions for
20 min at 23°C in a total volume of 10 p.1. In some experi-
ments, heparin (2 ,ug/p.l of extract) was added to splicing
buffer before incubation. This material was then added to the
antibody-bound protein A-Sepharose and incubated for 2 h
at 4°C with mixing. The resin was washed extensively with
the NET buffer used previously and phenol-chloroform
extracted, and the isolated RNAs were analyzed as de-
scribed below.
Analysis of 3'-end-labeled RNAs. In vitro labeling of RNAs
with [5'-32P]pCp and T4 RNA ligase was done essentially as
described elsewhere (S. Ruby, S. E. Goelz, Z. Hostomsky,
and J. Abelson, Methods Enzymol., in press). Immunopre-
VOL. 9, 1989
3712 BANROQUES AND ABELSON MOL. CELL. BIOL.
-211 TAGTGGTATC TGAAATATAT ATATACACAG TTTCTTAAAT TGTTGTCTTT ACTACTGGTA TTACTATCGC
-141 TATTACAAGC GAAGTCATTA AGTACGGAAA TGTTTAAACG TAGAGAGCTA GTAAAGGAAA GGCTGTTACA
-71 TGATCACTAA TCGTAACTTT GCAACGAGCC TGAGGGAAAT GACTAGTACT ATTACCTTGT TGAACGGAAT
1 ATG AGT AAA TAT ATT GCA CTT GAA AAT CTT CCG GTA GAT TTG CAA CAT AAA GGA GCT ACA
M S K Y I A L E N L P V D L Q H K G A T
61 CAA AAT GAA AGC ACC GCT GAT ATA CTG AAA CAG TTG CCA CAT GAA CGA TTA CAA GCT GTC
Q N E S T A D I L K Q L P H E R L Q A V
121 CTG GAG AAG ATA CCA GAA GAA GAT CTT GAG GTG AGA CGA TTG CTT TCA ATT TTA AAG AAG
L E K I P E E D L E V R R L L S I L K K
181 CCG GAA GTA
P E V
241 ATG GTT GAT
M V D
301 GTA GAC GAA
V D E
361 AGA AGA TTT
R R F
421 GAA AGA CAT
E R H
481 CGT ATG GCT
R M A
541 GTT TCT TTA
V S L
601 GTA TTA AAT
V L N
661 ATC GGA GCT
I G A
721 GGG CTC ATC
G L I
GTG GAG AAT GAA GAT GTA CAA CAA AGA AGA ATA CGG TTG GCT GAA ATT TTA
V E N E D V 0 Q R R I R L A E I L
GAA ATT GAT CTT GAG AAC ATT AAT AAC ATG GAA AAC ATA AAT GGG GAA GAA
E I D L E N I N N M E N I N G E E
GAG GAC GAT GAG GAC TTC TTC ACT CCA GCA ACA TCT GAG CTC ATT TTT GCG
E D D E D F F T P A T S E L I F A
TTG ATA AAT TAT TCA CTT GAA AGA TCT CGA AAG AGG CTA CAG AAA GAG ATG
L I N Y S L E R S R K R L Q K E M
CAA AAG TTC AAT ACA AGA CAG GAA TTA CTC AGT CGG CGT ACA GAA TTA CAG
Q K F N T R Q E L L S R R T E L 0
AAT TTA GAG CTT GCT GGC TCT CAA TTA GTA TCT ACG AAG CCT ATT TCC GCA
N L E L A G S Q L V S T K P I S A
TCT ACC GAT GAC ATG GTT GTC GCA ACG GGA AGC TGG GCA GGT GAT CTT CAG
S T D D M V V A T G S W A G D L Q
TCT CAA ACA CTG CAG CCA TTG ACA CAA AAA CTC GAC TCT CAT GTA GGG AAA
S Q T L Q P L T Q K L D S H V G K
ATA GAT TGG CAT CCT GAT TCA AAC AAT CAA ATG ATT TCA TGC GCA GAA GAC
I D W H P D S N N Q M I S C A E D
AAA AAC TTT CAA TAC TCA AAC GAA GAG GGC GGC CTT CGA TTA TTG GGA GAT
K N F 0 Y S N E E G G L R L L G D
781 CTT GTG GGA CAT GAA AGA CGT ATT TCT GAT GTG AAA TAC CAC CCT AGT GGC AAA TTT ATA
L V G H E R R I S D V K Y H P S G K F I
841 GGT AGT GCC TCT CAT GAT ATG ACT TGG AGA CTT TGG GAT GCG TCA ACA CAT CAA GAA CTG
G S A S H D M T W R L W D A S T H Q E L
901 CTG CTA CAA GAA GGC CAT GAT AAG GGA GTG TTT AGT CTG TCT TTT CAA TGC GAT GGA TCT
L L Q E G H D K G V F S L S F Q C D G S
961 CTT GTT TGT AGC GGT GGC ATG GAC TCG CTT TCA ATG CTA TGG GAT ATA AGA TCC GGA AGT
L V C S G G M D S L S M L W D I R S G S
1021 AAG GTG ATG ACA CTC GCA GGA CAC TCA AAG CCT ATT TAC ACC GTA GCT TGG TCA CCA AAC
K V M T L A G H S K P I Y T V A W S P N
1081 GGG TAT CAA GTA GCC ACT GGT GGT GGT GAT GGA ATC ATT AAT GTT TGG GAC ATC AGA AAA
G Y Q V A T G G G D G I I N V W D I R K
1141 CGG GAT GAA GGC CAA CTA AAT CAA ATA TTG GCG CAT CGT AAC ATC GTT ACG CAG GTA AGG
R D E G 0 L N 0 I L A H R N I V T 0 V R
1201 TTT TCA AAG GAA GAC GGC GGA AAG AAA CTT GTC TCT TGT GGC TAT GAT AAT TTG ATC AAT
F S K E D G G K K L V S C G Y D N L I N
1261 GTG TAT AGT AGT GAT ACG TGG TTA AAA ATG GGA AGT TTA GCA GGC CAC ACT GAT AAA ATT
V Y S S D T W L K M G S L A G H T D X I
1321 ATT AGC TTG GAT ATT TCG AAT AAT TCT CAT TTT TTA GTG AGC GGC GGA TGG GAT AGG TCT
I S L D I S N N S H F L V S G G w D R S
1381 ATC AAG CTC TGG AAT TGA TTGTGTAAAG AAATGTATTT AGTATTTTTG AAACTAACGT TTTATTAACA
I K L W N *
1449 CTGCATTATT TATTTMAATTA TACATTTCCT GGTTTMTTG CCCTGGATTT TTTTTTTGTG TTACCATTTT
1519 GAGTACGAAC TCGTGGAATT GTTAAGTTTT CCAAGTTGTC CATCGTCTTC GATAACTGTC CCACTAACTC
FIG. 1. Sequence of PRP4, including the PRP4-coding sequence as well as the 5'- and 3'-flanking regions. The nucleotide sequence and
the deduced amino acid sequence are shown. The DNA sequence is numbered starting from the first nucleotide of the initiation codon (ATG).
The underlined sequences represent the complementary sequences of the oligonucleotides used for site-specific mutagenesis.
PRP4: A U4/U6 snRNP 3713
cipitated RNAs were purified by phenol-chloroform extrac-
tion and ethanol precipitation in the presence of glycogen as
a carrier (20 ,g per reaction). These RNAs were added to a
10-pI reaction mixture containing cytidine 3',5'-[5'-32P]bis-
phosphate (80 ,uCi; 3,000 Ci/mmol) in 30 mM N-2-hydroxy-
ethylpiperazine-N-2'-ethanesulfonic acid (HEPES; pH 8.3)-
6 mM MgCl2-4 mM dithiothreitol-12 ,uM ATP-dimethyl
sulfoxide-10% 5% PEG 8000. The ligation reaction was
carried out for 4 h at room temperature in the presence of 20
U of RNasin (Promega Biotec). After ethanol precipitation,
the RNAs were separated by electrophoresis on a 6%
polyacrylamide-7 M urea gel with an acrylamide/bisacryla-
mide ratio of 29:1, followed by autoradiography.
Northern (RNA) blot analysis. RNAs from the gel were
electroblotted onto GeneScreen membrane (Dupont, NEN
Research Products) in 25 mM phosphate buffer (pH 6.5) for
16 to 18 h at 4°C and UV irradiated for 10 min to fix the
RNAs (13). Prehybridization and hybridization of blots were
carried out at 42°C in a solution containing 50% formamide,
25 mM sodium phosphate (pH 6.5), 6x SSC (SSC is 0.15 M
NaCl plus 0.015 M sodium citrate), 5x Denhardt solution,
0.5% SDS, and 0.1 mg of calf thymus DNA per ml. After
hybridization, membranes were washed twice for 5 min each
in 2x SSC-0.5% SDS, twice for 5 min each in 2x SSC-0.1%
SDS at room temperature, and once for 30 min at 60°C. The
U4, U5, and U6 probes were 32P end labeled by treating 20
pmol of synthetic oligonucleotides with polynucleotide ki-
nase as described by Maxam and Gilbert (33). The following
oligonucleotides were used as probes: a 45-mer (5'-ATT
CAAAGCGAACACGAATTGACCATGAGGAGACGGTC
TGGTTTA-3') complementary to residues 77 to 121 of yeast
U4 snRNA (42), a 35-mer (5'-CCTGTTTCTATGGAGACA
ACACCCGGATGGTTCTG-3') complementary to residues
101 to 136 of yeast U5 snRNA (36) and a 49-mer (5'-CAT
CCTTATGCAGGGGAACTGCTGATCATCTCTGTATTG
TTTCAAATTG-3') complementary to residues 34 to 82 of
yeast U6 snRNA (7). DNA fragments containing Ul (25, 43)
or a portion of the U2 (1) gene were used for synthesis of the
probes by the random-primer extension method of Feinberg
and Vogelstein (15). The U2 clone was provided by M. Ares,
and the Ul clone was provided by P. G. Siliciano.
RESULTS
Sequence of the PRP4 gene. We determined the DNA
sequence of both strands of the cloned yeast PRP4 gene by
the sequencing strategy described in Materials and Methods.
Figure 1 summarizes the DNA sequence of the gene and the
deduced amino acid sequence of the protein product.
Analysis of the sequence showed a single long open
reading frame 1,400 base pairs in length that could encode a
465-amino-acid protein with a predicted molecular weight of
52,418. A potential TATA box was found at about 190
nucleotides upstream of the ATG, and a T-rich transcription
termination sequence was found around 90 to 100 nucleo-
tides downstream of the stop codon. The sequence sur-
rounding the ATG fit the consensus sequence (AANAT-
GNNT) for highly expressed genes in yeast cells (18) but was
not maximal; PRP4 was not abundantly produced in yeast
cells.
The PRP4 protein sequence was compared with a collec-
tion of protein sequences in the BIONET data bases and
with the other known PRP protein sequences; no significant
homology was found.
Overproduction of PRP4 mediated by the T7 promoter in E.
coli. The PRP4 gene was inserted into the E. coli expression
% *-
-PRP4-'H( pJDB2071PRP4)
7 subelone H-B fragment into M13
_-Ac ( Ml3mpl8 I PRP4)
N
,
|5' ATATTTACCCAtGGTCCGTTC 3'
473 oligonudeotde mutagenesis
N N
e-~~~~F~ - a
ID subcbne NCO fragment into PAR 303911
T7(P) Tzm
..PRP 4....
(PAR 3039/1 PRP4)
4 cotransformation wnth pGPl-2
overproduction of PRP 4 in Ecoli
SCAL
1 kb
FIG. 2. Scheme for construction of the expression vector. The
Ball-HindIll fragment from pJDB207/PRP4 was subcloned into an
M13mpl8 vector. Site-specific mutagenesis was used to introduce
an NcoI site on both sites of the coding fragment. The asterisks
indicate base changes in the gene. The oligonucleotide sequences
are the reverse complement of the DNA sequence presented in Fig.
1. The expression vector was obtained by inserting the NcoI DNA
fragment into the unique cloning site of PAR3039/1 downstream of
the T7 polymerase promoter. Cotransformation with pGP1-2 and
PAR3039/1-PRP4 is required for overproduction of PRP4 in E. coli.
Sites for restriction enzymes used in cloning: B, BalI; H, HindIII;
N, NcoI. Positions of the T7 promoter T7(P) and the T7 transcrip-
tion terminator T7(T) are indicated.
vector PAR3039/1 under the control of the strong T7 tran-
scription-translation signals through the series of manipula-
tions shown in Fig. 2 (46, 47). The expression system used
consisted of the two compatible plasmids PAR3039/1 and
pGP1-2, described in Materials and Methods. When supplied
with the T7 polymerase in trans, PAR3039/1-PRP4 was
found to direct the synthesis of a large amount of PRP4,
observed as a strong band of 52 kDa on SDS-polyacrylamide
gels (Fig. 3A). In the absence of pGP1-2, or with a truncated
PRP4 gene (not shown), this 52-kDa band was not present.
When cultures of E. coli(PAR3039/1-PRP4)(pGP1-2) were
not induced, a low amount of PRP4 was detected, presum-
ably as a result of synthesis of a small amount of T7 RNA
polymerase.
There was a high level of expression of PRP4 in this
construct; PRP4 constituted 5 to 10% of the total cellular
protein in an induced culture. Like many proteins overpro-
duced in E. coli, PRP4 was insoluble in the absence of
detergent. We took advantage of this property during puri-
fication by reextracting the cell pellet with 0.5% SDS; this
provided a useful step in the purification scheme for this
protein.
Figure 3B shows the immunoblot analysis of a crude
extract prepared from the overproducing strain. A very
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FIG. 3. Overproduction of the PRP4 protein
Western blot (immunoblot) analysis of proteins
overproducing strain and in yeast cells. (A) Accun
in an overproducing strain. The two lanes represe
from cells harboring the plasmid PAR3039/1-PRP
absence of pGP1-2; lane 2, after heat induction an(
of pGP1-2). Samples were equivalent to 200 ,u1 of
analyzed on SDS-polyacrylamide gels stained with
Positions of molecular size markers are indicate
kilodaltons). (B) Immunoblot analysis. Extract
overproducing strain (equivalent of 50 ,ug of ce
phoresed on an SDS-polyacrylamide gel, transfer
lose, and hybridized with preimmune serum (I
antiserum against PRP4 (lane 2) at a dilution of 1
sample of yeast splicing extract from the wild-type
of yeast extract from the strain transformed witl
was immunoblotted and incubated with anti-PRPX
dilution of 1:2,500 (lanes 4 and 5, respectively).
preimmune serum (lane 3) was run in parallel. Posit
protein are indicated (A).
4 5 strong band could be easily detected by the anti-PRP4
antibodies used at a 1:20,000 serum dilution (lane 2). In
absence of pGP1-2, no protein was detected (lane 1). More-
over, no band corresponding to this molecular weight could
be detected by the preimmune serum used at the same
dilution; only a few faint bands corresponding to nonspecific
cross-reacting species of low molecular weight could be
found (not shown).
Immunoblot analysis of yeast extracts. The anti-PRP4 anti-
bodies appeared to react specifically with a single protein of
the yeast splicing extract (Fig. 3B, lane 4). The intensity of
the band observed on the immunoblot increased when the
experiment was done with a strain transformed with a
multicopy plasmid carrying the PRP4 gene (lane 5). At
antibody concentrations higher than the 1:2,500 dilution
shown, some cross-reacting species of lower molecular
weight appeared. The anti-PRP4 antibodies, however, were
clearly specific for yeast PRP4. No proteins were detected
with the preimmune serum (lane 3).
(: ~) Requirement of PRP4 for in vitro mRNA splicing. An
in E. coli and antibody inhibition experiment was used to determine
in the E. coli whether PRP4 plays a critical role in the in vitro mRNA-
nulation of PRP4 splicing reaction. The in vitro mRNA-splicing reaction was
nt total proteins completely inhibited by the addition of 7.5 to 20 ,ug of PRP4
'4 (lane 1, in the protein A-purified antibody to 4 p.l of splicing extract (Fig.
d in the presence 4). In contrast, addition of preimmune serum had no effect
culture and were on splicing.
Coomassie blue. U4, U5, and U6 snRNAs coprecipitate with PRP4. The
d on the left (in possibility that PRP4 is associated with snRNAs was inves-
from the PRP4- tigated by immunoprecipitation of yeast extracts with anti-
red to nitrocellu- PRP4 antibodies at various ionic strengths. The RNA spe-lane 1) or with cies immunoprecipitated were analyzed by Northern
1:20,000 A 40wit blotting, using labeled snRNA probes. When the immuno-
strain and 10 ,ul precipitation was done at 150 mM salt, three snRNAs
h pJDB207/PRP4 corresponding to U4, US (short and long forms), and U6
4 antibodies at a were found (Fig. 5, lanes 4 and 5). There was an increase in
The control with the precipitation of U4 and U6 if the splicing extract was first
tLions of the PRP4 incubated with 2 mM ATP. Preimmune serum did not
precipitate any snRNA (lanes 2 and 3). Anti-m3G antibodies
also immunoprecipitated the U4, U5, and U6 snRNAs in
addition to Ul and U2 snRNAs (lane 6) as a consequence of
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FIG. 4. Inhibition of mRNA splicing by anti-PRP4 antibodies. Wild-type splicing extract (4 ,ul) was preincubated with buffer D (lane 1),
with 3 or 15 p.g of preimmune IgG (lanes 2 and 3), or with 0.2, 0.3, 0.5, 0.7, 1, 3, 5, 7.5, 10, 15, or 20 p.g of anti-PRP4 IgG (lanes 4 to 14) for
30 min at 4°C. A standard mRNA-slicing reaction was then carried out by using uncapped actin pre-mRNA as substrate, and the RNAs were
analyzed on an 8% acrylamide-7 M urea gel. IVS-E2, Lariat intron-exon 2; IVS, excised lariat intron; E1-E2, spliced message.
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FIG. 5. Coprecipitation of snRNAs with PRP4. Splicing extract
(4 ,ul) was preincubated at 23°C for 20 min under splicing conditions
in the absence of ATP (lanes 2 and 4) or in the presence of 2 mM
ATP (lanes 3, 5, and 6) and then subjected to immunoprecipitation
with preimmune serum (lanes 2 and 3) anti-PRP4 antibodies (lanes 4
and 5), or anti-m3G antibodies (lane 6). Incubation of the extract
with antibodies and subsequent washes were done in 150 mM salt.
RNAs were recovered from immune complexes, analyzed by elec-
trophoresis on a 6% acrylamide-7 M urea gel, and probed with
labeled snRNA probes as described in Materials and Methods. Lane
1 shows total RNAs from 0.5 ,u of crude splicing extract.
the trimethylguanosine cap structure at their 5' ends. U6 has
no cap structure, but it can be immunoprecipitated because
of its association with U4 (42). The snRNA species precip-
itated by the anti-PRP4 antibodies or by the anti-m3G
antibodies were in the same relative proportions as observed
in the total snRNAs found in the splicing extract. However,
the amount of snRNAs immunoprecipitable by anti-PRP4
antibody represented only 10 to 15% of the total snRNAs.
Other snRNAs coprecipitate with PRP4 at low ionic
strengths. Since snRNAs coprecipitated with PRP4, it was
interesting to analyze which snRNAs were immunoprecipi-
tated under less stringent conditions. Surprisingly, in the
absence of salt, all of the snRNAs precipitated with PRP4
(data not shown); Ul and U2 were particularly abundant
under these conditions. The amount of Ul and U2 precip-
itated decreased progressively when the salt concentration
was raised to 85 mM (data not shown).
To determine whether these results reflected specific
interactions between PRP4 and the snRNAs, all of the RNAs
recovered from the immunoprecipitates were 3' end labeled
and then analyzed by urea-gel electrophoresis. A marked
increase in the amount of RNA contaminants, as well as
other snRNAs immunoprecipitated with anti-m3G or anti-
PRP4 antibodies, was observed at lower ionic strengths.
When the immunoprecipitation was done at 50 mM NaCl or
in the absence of salt, Ul, U2, U4, and U5 were immuno-
precipitated along with some other snRNAs and 5S, 5.8S,
and large rRNAs (Fig. 6). When the stringency of the
immunoprecipitation conditions was raised, the contami-
nants in the immunoprecipitation decreased, as did the
amount of Ul and U2 precipitated. Only U4 and U5 were
visible after immunoprecipitation with anti-PRP4 antibodies
at 150 mM NaCl; the other snRNAs were no longer immu-
- U2
I
- ul
t4
U 5
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5.8s rRNA _
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1234 567 8910
FIG. 6. Coprecipitation of the Ul, U2, U5, and U4/U6 snRNPs
with PRP4 in low salt. After preincubation in the absence or
presence of 2 mM ATP as indicated, splicing extracts were sub-
jected to immunoprecipitation with preimmune serum (lanes 1 and
5), anti-m3G antibodies (lanes 2, 6, and 8), or anti-PRP4 antibodies
(lanes 3, 4, 7, 9, and 10) under different salt conditions (0, 50, or 150
mM NaCl). The RNAs recovered from the immune complexes were
labeled in a standard 3'-end-labeling reaction. The two first lanes
show the in vitro transcripts of the yeast Ul, U2, U4, and U5 (long
form) snRNAs.
noprecipitated. Because U6 is a poor substrate for the
3'-end-labeling reaction, it cannot be detected by this
method. No detectable snRNAs were immunoprecipitated
with the preimmune serum. In summary, we showed that the
PRP4 protein could be coprecipitated with the five snRNAs
under low ionic strength conditions; RNA contaminants
were also precipitated but to a lesser extent.
PRP4 is strongly associated with U4/U6 snRNP. By raising
the stringency of the immunoprecipitation conditions, we
wanted to determine whether PRP4 was associated more
specifically and more tightly with one particular snRNP.
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FIG. 7. Demonstration that PRP4 is a U4/U6 snRNP-binding protein. Splicing extract was subjected to immunoprecipitation with
anti-PRP4 antibodies under the salt conditions indicated. (A) Preincubation in the absence or the presence of 2 mM ATP; (B) preincubation
under the same conditions except that heparin (2 ,ug/,ul of extract) was added.
Precipitation of U4, U5, and U6 was stable to salt concen-
trations up to 250 mM but was destabilized at higher con-
centrations: when the salt concentration was raised to 500
mM or even 750 mM, only U4 and U6 snRNAs were
immunoprecipitated (Fig. 7A). PRP4 is therefore strongly
associated with the U4/U6 snRNP. At high cation concen-
trations, immunoprecipitation was highly dependent on the
presence or absence ofATP during the preincubation. At 750
mM NaCl, U4 and U6 snRNAs could be detected only when
yeast extract was preincubated in the absence of ATP in the
splicing buffer. However, the same relative amounts of U4
and U6 snRNAs were found in the immune complexes,
independently of the salt or the presence or the absence of
ATP.
To confirm that PRP4 is a component of the U4/U6
snRNP, we performed the immunoprecipitation after treat-
ing the extract with heparin (2 ,ug/,lI of extract) as described
in Materials and Methods. Heparin has previously been used
to eliminate nonspecific binding of proteins to RNAs (21).
Figure 7B shows the results of the immunoprecipitations
done under different salt conditions. U2 was released first,
which indicated that the association of U2 with PRP4 was
very sensitive to heparin. Then Ul was released from the
complex, followed by U5. It is interesting that the two forms
of U5 were released at the same time. U4 and U6 were the
last snRNAs to be released from the complex. Therefore,
PRP4 is tightly associated with the U4/U6 snRNAs.
PRP4 is required early in the splicing pathway. Yeast actin
pre-mRNA splicing studies (11, 38) have shown that at least
four kinetically related complexes can be resolved by elec-
trophoresis on native polyacrylamide gels. It has been
shown that the earliest detectable complex (complex B [11])
contains only the U2 snRNP; then the U4, U5, and U6
snRNPs joint the complex. (The Ul snRNP could not be
detected by the nondenaturing gel analysis [39]). When
anti-PRP4 antibodies were added to a splicing reaction
before separation of the splicing reaction mixtures on non-
denaturing polyacrylamide gels, only complex B accumu-
lated after 10 min of incubation (Fig. 8). The PRP4 gene
product and the U5 and U4/U6 snRNPs were required for
further assembly of the spliceosome. The preimmune serum
had no effect on spliceosome assembly; complexes B, Al,
and A2 were all observed, in accordance with the assembly
pathway proposed by Cheng and Abelson (11).
DISCUSSION
Genetic and biochemical evidence has accumulated dem-
onstrating that the protein products of the genes PRP2 to
PRPIJ are essential components in yeast mRNA splicing
and that most of the encoded proteins are required for in
vitro spliceosome formation (10, 27, 29, 31); however, a
specific function has not yet been determined for any of
these proteins. Immunological procedures represent a pow-
erful approach to the analysis of complexes containing a
particular protein. Using this approach, Lossky et al. have
been able to show that PRP8 is an snRNP protein that is
specific to the U5 snRNP (29). In this study, we demon-
strated that the 52-kDa protein encoded by the PRP4 gene of
S. cerevisiae also is a component of snRNPs. We showed
that PRP4 is a U4/U6 snRNP protein that is also present in
the larger U4/US/U6 complex. Moreover, we showed that
PRP4 is required for in vitro mRNA splicing at an early stage
in the spliceosome assembly pathway.
We have used immunoprecipitation experiments to dem-
onstrate that PRP4 is tightly associated with U4 and U6
snRNAs. By Northern blot analysis of snRNP components
on nondenaturing gels, Cheng and Abelson (11) observed
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FIG. 8. Inhibition of spliceosome assembly by addition of anti-
PRP4 antibodies. Splicing extract (2 ,ul) was preincubated with
buffer D (control), preimmune IgG (10 ,ug), or anti-PRP4 IgG (0.1,
0.5, 2.5, or 10 F±g) at 0°C for 10 min; then standard splicing reactions
were carried out for 10 min at 23°C. The complexes were separated
by electrophoresis on a native polyacrylamide gel.
that U6 could exist as a separate U6 snRNP, in contrast with
the "virtual absence" of separate U4 snRNP in yeast
extract. The fact that U4 and U6 were always immunopre-
cipitated together in the same relative ratio regardless of the
conditions used strongly suggests that PRP4 is a component
of the U4/U6 snRNP. Furthermore, since the same relative
amounts of U4 and U6 were observed both with the anti-
m3G and anti-PRP4 antibodies, PRP4 does not seem to be
associated with the separate U6 snRNP.
PRP4 was also found to be associated with the two forms
of U5 snRNA. It has previously been shown that in yeast the
U4/U6 and U5 snRNPs are associated in a large U4/U5/U6
particle (11). A similar complex has been found in mamma-
lian cells (22). In yeast cells, this particle was described as
being very stable in vitro under a variety of conditions, but
it could be dissociated at high salt concentrations to give a
free U5 snRNP and a complex containing both U4 and U6
snRNAs (11). When the salt concentration in the immuno-
precipitations was raised to 350 mM (data not shown), U5
dissociated from the large complex, since only U4 and U6
snRNAs, not U5, were immunoprecipitated by the anti-
PRP4 antibodies. This result indicates that PRP4 is not a
component of the U5 snRNP. The U5 snRNP can be
immunoprecipitated only through snRNP-snRNP interac-
tions. When the interactions between U5 and U4/U6 sn-
RNPs were destabilized (by high salt concentrations or by
heparin treatment), U5 was no longer immunoprecipitated.
In addition, antibodies against PRP4 were able to mediate
the coprecipitation of Ul and U2 snRNAs along with the
U4/U51U6 particle at very low ionic strengths. This obser-
vation might indicate that PRP4 is associated with each
snRNP, leading to precipitation of each particle indepen-
dently. This seems unlikely for several reasons. First, sig-
nificant amounts of other snRNAs as well as RNA contam-
inants (rRNAs) have been immunoprecipitated under these
conditions. Second, we found no conditions under which
only Ul or U2 could be immunoprecipitated. Finally, Ul and
U2 were no longer precipitated when the conditions were
more stringent (high salt concentrations or the presence of
heparin). It seems more likely that Ul and U2 snRNAs were
immunoprecipitated via snRNP-snRNP interactions with the
U4/U5/U6 particle. By comparison, it is interesting to note
that the anti-PRP8 antibodies were able to precipitate signif-
icant amounts of RNA contaminants but only U5 snRNA
under the less stringent conditions; Ul, U2, U4, and U6
were not precipitated (data not shown). A similar set of
snRNPs associated in the absence of pre-RNA during incu-
bation of the extract in 250 mM NH4Cl has been described in
mammalian cells by Konarska and Sharp (23).
Splicing complex containing intermediates, products, and
pre-mRNA could not be immunoprecipitated by the anti-
PRP4 antibodies under normal salt conditions but only under
low-salt conditions (data not shown). The simplest interpre-
tation of this result is that the anti-PRP4 antibodies were able
to precipitate the U41U5/U6 complex before it became
associated with the pre-mRNA; once this particle became
associated with the U2-pre-mRNA complex, the antigenic
sites of PRP4 become inaccessible to the antibodies. At low
salt concentrations, the conformation of the large complex
may be different and the antigenic sites more accessible.
Our results showed that the U41U5/U6 complex was
precipitated by anti-PRP4 antibodies both in the presence
and in the absence of ATP. Previously, Lossky et al. (29)
observed that this complex could be precipitated by anti-
PRP8 antibodies only after preincubation with ATP. We are
currently investigating this discrepancy. It could be due to
differing procedures or to differences in the ATP level in
extracts or in the endogenous level of the U4/U5/U6 com-
plex. Cheng and Abelson (11) previously observed that the
U41U5/U6 complex, as detected on nondenaturing gels, is
dissociated by ATP. The results presented here suggest that
this dissociation may be a heparin-ATP effect. Treatment of
extracts with heparin (at the concentration used in the
nondenaturing gel separation) and ATP (2 mM) resulted only
in the anti-PRP4 precipitation of U4 and U6 (Fig. 7B). By
inducing conformational changes in the snRNPs (2, 3, 24),
ATP may make the complex sensitive to dissociation by
heparin.
Results of the antibody inhibition experiment confirmed
those previously obtained (31) and suggest that PRP4 is
essential for mRNA splicing. As was found with the anti-
m3G antibodies (10), the anti-PRP4 antibodies completely
abolished the splicing reaction. Both steps of splicing were
inhibited, indicating that the antibodies blocked the reaction
before cleavage at the 3' end of the upstream exon and the
formation of the intron lariat. Four splicing complexes that
Antibod,
A
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form sequentially during the course of the reaction have
been described (11). Complex B, containing predominantly
pre-mRNA bound to U2 snRNP, is the first detectable
intermediate. Formation of the later complexes requires the
association of U5 and U4/U6 snRNPs with the pre-mRNA.
Removal of the snRNPs associated with PRP4 by the anti-
bodies inhibits the formation of these complexes and results
in the accumulation of complex B. This indicates that PRP4
is involved early in the spliceosome formation and is consis-
tent with the current models for spliceosome assembly. This
result also argues against the possibility that PRP4 is present
in the Ul and U2 snRNPs.
In mammalian cells, no protein unique to the U4/U6
particle has yet been identified. PRP4 is the first protein
described that is specific to the yeast U4/U6 snRNP. An-
other snRNP protein, called PRP8, that is found to be
specific for the U5 snRNP has been described by Lossky et
al. (29). It is interesting that the anti-PRP8 antibodies were
also able to immunoprecipitate the U41U5/U6 particle under
some conditions. Up to now, PRP4 and PRP8 were the only
snRNP proteins found to be involved in yeast mRNA
splicing. The antibodies now make it possible to investigate
the protein composition of the U4/U6 snRNP in yeast cells.
It is interesting that extra copies of PRP3 (26) are able to
relieve the lethality of prp4 at restrictive temperatures,
suggesting that PRP4 and PRP3 may interact in the same
snRNP and may have related functions. No specific binding
site for the U4/U6 particle in the splicing complex has been
yet identified, and its role is still unknown. The high degree
of evolutionary sequence conservation in U6 snRNA (7)
suggests that the U4/U6 snRNP may have a central position
in the splicing complex and may be in close contact with a
number of components of the spliceosome (8). Moreover,
there are several domains highly conserved in these two
snRNAs which can constitute a recognition site for binding
proteins. It will be interesting to determine whether PRP4
binds specifically to U4 or U6 and to investigate the role of
PRP4 in yeast pre-mRNA splicing.
ACKNOWLEDGMENTS
We thank J. Beggs and R. Luhrmann for the generous gift of
anti-PRP8 and anti-m3G antibodies and J. Woolford for providing
the PRP4 yeast pJDB207/PRP4 plasmid. We are grateful to S.-C.
Cheng for help with nondenaturing gels and to G. Komatsoulis and
G. McFarland for help with computer analysis. We gratefully
acknowledge K. Tanner, P. Fabrizio, G. McFarland, and J. Arenas
for critical readings of the manuscript. We also thank S. Horvath for
synthesizing oligonucleotides and C. Blagg for typing the manu-
script.
J.B. was a recipient of NATO and CNRS/NSF fellowships. This
work was supported by Public Health Service grant GM 32637 from
the National Institute of Health.
LITERATURE CITED
1. Ares, M. 1986. U2 RNA from yeast is unexpectedly large and
contains homology to vertebrate U4, U5, and U6 small nuclear
RNAs. Cell 47:49-59.
2. Black, D. L., B. Chabot, and J. A. Steitz. 1985. U2 as well as Ul
small nuclear ribonucleoproteins are involved in pre-mRNA
splicing. Cell 42:737-750.
3. Black, D. L., and J. A. Steitz. 1986. Pre-mRNA splicing in vitro
requires intact U4/U6 small nuclear ribonucleoprotein. Cell
46:697-704.
4. Bringmann, P., B. Appel, J. Rinke, R. Reuter, H. Theissen, and
R. Luhrmann. 1984. Evidence for the existence of snRNAs U4
and U6 in a single ribonucleoprotein complex and for their
association by inter-molecular base-pairing. EMBO J. 3:1357-
1363.
5. Bringmann, P., R. Renter, J. Rinke, B. Appel, R. Bald, and R.
Luhrmann. 1983. 5'-Terminal caps of snRNAs are accessible for
reaction with 2,2,7-trimethylguanosine-specific antibody in in-
tact snRNPs. J. Biol. Chem. 258:2745-2747.
6. Brody, E., and J. Abelson. 1985. The "spliceosome": a yeast
pre-messenger RNA associates with a 40S complex in a splicing-
dependent reaction. Science 228:963-967.
7. Brow, D. A., and C. Guthrie. 1988. Spliceosomal RNA U6 is
remarkably conserved from yeast to mammals. Nature
(London) 334:213-218.
8. Brow, D. A., and C. Guthrie. 1989. Splicing a spliceosomal
RNA. Nature (London) 337:14-15.
9. Chabot B., and J. A. Steitz. 1987. Multiple interactions between
the splicing substrate and small nuclear ribonucleoproteins in
spliceosomes. Mol. Cell. Biol. 7:281-293.
10. Chang, T. H., M. W. Clark, A. J. Lustig, M. E. Cusick, and J.
Abelson. 1988. RNA11 protein is associated with the yeast
spliceosome and is localized in the periphery of the cell nucleus.
Mol. Cell. Biol. 8:2379-2393.
11. Cheng, S.-C., and J. Abelson. 1987. Spliceosome assembly in
yeast. Genes Dev. 1:1014-1027.
12. Choi, Y. D., P. J. Grabowski, P. A. Sharp, and G. Dreyfuss.
1986. Heterogeneous nuclear ribonucleoproteins: role in RNA
splicing. Science 231:1534-1539.
13. Church, G. M., and W. Gilbert. 1984. Genomic sequencing.
Proc. Natl. Acad. Sci. USA 81:1991-1995.
14. Clark, M. W., and J. Abelson. 1987. The subnuclear localization
of tRNA ligase in yeast. J. Cell. Biol. 105:1515-1526.
15. Feinberg, A. P., and B. Vogelstein. 1983. A technique for
radiolabeling DNA restriction endonuclease fragments to high
specific activity. Anal. Biochem. 132:6-13.
16. Frendewey, D., and W. Keller. 1985. The stepwise assembly of
a pre-mRNA splicing complex requires U-snRNPs and specific
intron sequences. Cell 42:355-367.
17. Grabowski, P. J., S. R. Seiler, and P. A. Sharp. 1985. A
multicomponent complex is involved in the splicing of messen-
ger RNA precursors. Cell 42:345-353.
17a.Guthrie, C., and B. Patterson. 1988. Spliceosomal snRNAs.
Annu. Rev. Genet. 22:387-418.
18. Haimilton, R., C. K. Watanabe, and H. A. de Boer. 1987.
Compilation and comparison of the sequence context around
the AUG start codons in Saccharomyces cerevisiae mRNAs.
Nucleic Acids Res. 15:3581-3593.
19. Hartweil, H. L. 1967. Macromolecule synthesis in temperature-
sensitive mutants of yeast. J. Bacteriol. 93:1662-1670.
20. Hashimoto, C., and J. A. Steitz. 1984. U4 and U6 RNAs coexist
in a single small ribonucleoprotein particle. Nucleic Acids Res.
12:3283-3293.
21. Konarska, M. M., and P. A. Sharp. 1986. Electrophoretic
separation of complexes involved in the splicing of precursors to
mRNAs. Cell 46:845-855.
22. Konarska, M. M., and P. A. Sharp. 1987. Interactions between
small nuclear ribonucleoprotein particles in formation of spli-
ceosomes. Cell 49:763-774.
23. Konarska, M. M., and P. A. Sharp. 1988. Association of U2,
U4, U5; and U6 small nuclear ribonucleoproteins in a spliceo-
some-type complex in absence of precursor RNA. Proc. Natl.
Acad. Sci. USA 85:5459-5462.
24. Krainer, A. R., and T. Maniatis. 1985. Multiple factors including
the small nuclear ribonucleoproteins Ul and U2 are necessary
for pre-mRNA splicing in vitro. Cell 42:725-736.
25. Kretzen, L., B. C. Rymond, and M. Rosbash. 1987. S. cerevisiae
Ul RNA is large and has limited primary sequence homology to
metazoan Ul snRNA. Cell 50:593-602.
26. Last, R. L., J. R. Maddock, and J. L. Woolford, Jr. 1987.
Evidence for related functions of the RNA genes of Saccharo-
myces cerevisiae. Genetics 117:619-631.
27. Lin, R. J., A. J. Lustig, and J. Abelson. 1987. Splicing of yeast
nuclear pre-mRNA in vitro requires a functional 40S spliceo-
some and several extrinsic factors. Genes Dev. 1:7-18.
28. Lin, R. J., A. J. Newman, S.-C. Cheng, and J. Abelson. 1985.
Yeast mRNA splicing in vitro. J. Biol. Chem. 260:14780-14792.
29. Lossky, M., G. J. Anderson, S. P. Jackson, and J. Beggs. 1987.
MOL. CELL. BIOL.
PRP4: A U4/U6 snRNP 3719
Identification of a yeast snRNP protein and detection of snRNP-
snRNP interactions. Cell 51:1019-1026.
30. Luhrmann, R. 1988. snRNP proteins, p. 71-99. In M. L.
Birnstiel (ed.), Structure and function of major and minor small
nuclear ribonucleoprotein particles. Springer-Verlag KG, Ber-
lin.
31. Lustig, A. J., R. J. Lin, and J. Abelson. 1986. The yeast RNA
gene products are essential for mRNA splicing in vitro. Cell
47:953-963.
32. Maniatis, T., and R. Reed. 1987. The role of small nuclear
ribonucleoprotein particles in pre-mRNA splicing. Nature
(London) 325:673-678.
33. Maxam, A. M., and W. Gilbert. 1977. A new method for
sequencing DNA. Proc. Natl. Acad. Sci. USA 74:560-564.
34. Mott, J. E., R. A. Grant, Y.-S. Ho, and T. Platt. 1985. Maxi-
mizing gene expression from plasmid vectors containing the XPL
promoter: strategies for overproducing transcription termina-
tion factor p. Proc. Natl. Acad. Sci. USA 82:88-92.
35. Newman, A. J., R. J. Lin, S.-C. Cheng, and J. Abelson. 1985.
Molecular consequences of specific intron mutations on yeast
mRNA splicing in vivo and in vitro. Cell 42:335-344.
36. Patterson, B., and C. Guthrie. 1987. An essential yeast snRNA
with a U5-like domain is required for splicing in vivo. Cell
49:613-624.
37. Phizicky, E., R. C. Schwartz, and J. Abelson. 1986. Saccharo-
myces cerevisiae tRNA ligase. J. Biol. Chem. 261:2978-2986.
38. Pikielny, C. W., B. C. Rymond, and M. Rosbash. 1986. Electro-
phoresis of ribonucleoproteins reveals an ordered assembly
pathway of yeast splicing complexes. Nature (London) 324:
341-345.
39. Ruby, S. W., and J. Abelson. 1988. An early and hierarchic role
of the Ul snRNP in spliceosome assembly. Science 242:1028-
1035.
40. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequenc-
ing with chain-terminating inhibitors. Proc. Natl. Acad. Sci.
USA 74:5463-5467.
41. Sharp, P. A. 1987. Splicing of messenger RNA precursors.
Science 235:766-771.
42. Siliciano, P. G., D. A. Brow, H. Roiha, and C. Guthrie. 1987. An
essential snRNA from S. cerevisiae has properties predicted for
U4, including interaction with a U6-like snRNA. Cell 50:
585-592.
43. Siliciano, P. G., M. H. Jones, and C. Guthrie. 1987. S. cerevisiae
has a Ul-like snRNA with unexpected properties. Science
237:1484-1487.
44. Soltyk, A., M. Tropak, and J. D. Friesen. 1984. Isolation and
characterization of the RNA2+, RNA4+, and RNAII+ genes of
Saccharomyces cerevisiae. J. Bacteriol. 160:1093-1100.
45. Steitz, J. A., D. Black, V. Gerke, K. A. Parker, A. Kramer, D.
Frendewey, and W. Keller. 1988. Functions of the abundant
U-snRNPs, p. 115-154. In M. L. Birnstiel (ed.), Structure and
function of major and minor small nuclear ribonucleoprotein
particles. Springer-Verlag KG, Berlin.
46. Studier, F. W., and B. A. Moffatt. 1986. Use of bacteriophage T7
RNA polymerase to direct selective high-level expression of
cloned genes. J. Mol. Biol. 189:113-130.
47. Tabor, S., and C. C. Richardson. 1985. A bacteriophage T7
RNA polymerase/promoter system for controlled exclusive
expression of specific genes. Proc. Natl. Acad. Sci. USA
82:1074-1078.
48. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose
sheets: procedure and some applications. Proc. Natl. Acad. Sci.
USA 79:5188-5189.
49. Zerbib, D., M. Jakowec, P. Prentki, D. J. Galas, and M.
Chandler. 1987. Expression of proteins essential for IS1 trans-
position: specific binding of InsA to the ends of IS1. EMBO J.
6:3163-3169.
VOL. 9, 1989
